Voyager Therapeutics (VYGR) Stock Statistics & Valuation Metrics

Voyager Therapeutics has a market cap or net worth of $170.16M. The enterprise value is $137.40M.

Voyager Therapeutics has 55,336,445 shares outstanding. The number of shares has decreased by -2.65% in one year.

Voyager Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -24.01%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Voyager Therapeutics had revenue of 80.00M and earned -65.00M in profits. Earnings per share was -1.13.

In the last 12 months, operating cash flow was -111.97M and capital expenditures -2.04M, giving a free cash flow of -114.01M billion.

Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Voyager Therapeutics upcoming earnings date is Jul 31, 2025, TBA (Confirmed).

Voyager Therapeutics as a current ratio of 5.56, with Debt / Equity ratio of 15.40%

In the past 12 months, Voyager Therapeutics has paid 665.00K in taxes.

Voyager Therapeutics EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -15.90.

Voyager Therapeutics has $236.02M in cash and marketable securities with $42.00M in debt, giving a net cash position of -$194.02M billion.

Gross margin is 48.55%, with operating margin of -104.11%, and net profit margin of -81.25%.

The average price target for Voyager Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy